[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant

604. Molecular Pharmacology, Drug Resistance: Poster III

Program: Oral and Poster Abstracts
Type: Poster
Monday, December 12, 2011: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Daunorubicin -TiO2 Nanocomposites As ‘smart’ pH-Responsive Drug Delivery System

Hai-jun Zhang1* and Bao-An Chen, MD, PhD2

1Department of Hematology and Oncology, The affiliated Zhongda Hospital, Medical School, Southeast University, Nanjing, China
2Department of Hematology and Oncology, The affiliated Zhongda Hospital, Medical School, Southeast University, Nanjing, China, Nanjing, China

A 2-Part Phase I Study in Patients with Solid or Hematologic Malignancies: Dose Proportionality of Subcutaneous (SC) Azacitidine (AZA) and Pharmacokinetics of SC AZA in Patients with Severe Renal Impairment

Eric Laille, MS1*, Alain C. Mita, MD2*, Sanjay Goel, MD, MS3*, Nashat Y. Gabrail, MD4*, Joseph Schwarz, MBA1* and CL Beach, PharmD1*

1Celgene Corporation, Summit, NJ
2University of Texas Health Science Center at San Antonio, San Antonio, TX
3Montefiore Einstein Cancer Center, Bronx, NY
4Gabrail Cancer Center, Canton, OH

Expression of Ara-C Metabolizing Enzymes Mediates in Vitro Sensitivity to Ara-C in Primary AML Cells From Patients with Denovo AML

Ajay Abraham, M.Sc1*, Savitha Varatharajan, M.Sc1*, Ashok kumar Jayavelu, M.Sc1*, Shaji R Velayudhan, M.Sc, Ph.D1*, Rayaz Ahmed, MD1*, Aby Abraham, MD1*, Biju George, MD1*, Mammen Chandy, MD1*, Alok Srivastava, MD1, Vikram Mathews, MD1 and Poonkuzhali Balasubramanian, M.Sc., Ph.D2

1Department of Haematology, Christian Medical College, Vellore, India
2Department of Haematology, Christian Medical College, Vellore- 632004, India

Effectiveness of Transcriptional CDK Inhibitors in Targeting Non-Proliferating CD34+CD38- AML Cells

Monica Pallis, PhD1*, Francis Burrows, PhD2*, Abigail Whittall, B Med Sci3*, Claire Seedhouse, PhD4*, Nicholas Boddy, B Med Sci3* and Nigel H. Russell, MD5

1Academic Haematology, Nottingham University Hospitals, Nottingham, United Kingdom
2Tragara Pharmaceuticals, San Diego, CA
3Haematology, University of Nottingham, Nottingham, United Kingdom
4Academic Haematology, University of Nottingham, Nottingham, United Kingdom
5Clinical Haematology, Nottingham City Hospital, Nottingham, United Kingdom

Smoothened (SMO), a G-Protein-Coupled Receptor (GPCR) Activated by Hedgehog Ligands, Modulates the Activity Levels of PI3K/AKT and NF-Kβ in Diffuse Large B-Cell Lymphoma

Changju Qu, MD PhD*, Yadong Liu, MD*, Kranthi Kunkalla, MS*, Nitin K Agarwal, PhD*, Estelle Bourbon, MS*, Lan V Pham, PhD*, Richard J. Ford, MD, PhD, Rajesh Singh, PhD* and Francisco Vega, MD, PhD

Department of Hematopathology, UT MD Anderson Cancer Center, Houston, TX

Small-Molecule Inhibition of BRD4 Is a Novel Promising Approach to Therapeutically Target Leukemia Stem Cells in AML

Harald Herrmann, M.D.1*, Katharina Blatt, M.Sc.2*, Junwei Shi3*, Amy R. Rappaport3*, Karoline V. Gleixner, M.D.2*, Sabine Cerny-Reiterer, D.V.M.2*, Barbara Peter, D.V.M.1*, Eric Wang3*, Wolfgang R. Sperr, M.D.2*, James E. Bradner, MD4, Scott W. Lowe, Ph.D.3,5*, Christopher R. Vakoc, M.D., Ph.D.3*, Johannes Zuber, M.D.3,6* and Peter Valent, M.D.1,2

1Ludwig Boltzmann Cluster Oncology, Vienna, Austria
2Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
3Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
4Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
5Howard Hughes Medical Institute, Cold Spring Harbor, NY
6Research Institute of Molecular Pathology (IMP), Vienna, Austria

Clinical Development of AVL-292; A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies

Erica Evans, PhD1*, Richland Tester, PhD1*, Sharon Aslanian1*, Prasoon Chaturvedi, PhD1*, Hormoz Mazdiyasni1*, Sabine Ponader, PhD2*, Bethany Tesar3*, Michael Sheets1*, Mariana Nacht, PhD1*, Kathryn Stiede1*, Steve Witowski, PhD1*, Heather Lounsbury1*, Russell Petter, PhD1*, Jennifer R. Brown, MD, PhD4, Jan A. Burger, MD, PhD5, Juswinder Singh, PhD6* and William F. Westlin, PhD1*

1Avila Therapeutics, Bedford, MA
2Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, TX
3Medical Oncology, Dana Farber Cancer Institute, Boston, MA
4Dana-Farber Cancer Institute, Boston, MA
5The University of Texas MD Anderson Cancer Center; Leukemia Department , Houston, TX
6Avila Therapeutics Inc., Bedford, MA

C-Jun Regulates Glucocorticoid-Mediated BIM Induction and Apoptosis in Leukemia Cells: An Alternative Target to Overcome Glucocorticoid-Resistance

Nastaran Heidari, PhD*, Christine B Marking*, Mark A Hicks* and Hisashi Harada, PhD

Virginia Commonwealth University, Richmond, VA

Polymorphisms in Exons 2 and 7 of the Human Organic Cation Transporter (hOCT1) (Solute Carrier Family 22, SLC22A1): Correlation with Imatinib Levels and Clinical Course in Chronic Myeloid Leukemia Patients 

Jacob Vine, medical student1*, Sara Bar Cohen, PhD2*, Rosa Ruchlemer, MD3, Neta Goldschmidt, MD2*, Moshe Levin, MD4, Diana Libster, MD4, Alexander Gural, MD2*, Moshe E. Gatt, MD2, David Lavie2*, Dina Ben-Yehuda, MD2 and Deborah Rund, MD2

1Medicine, Hebrew University-Hadassah Medical School, Jerusalem, Israel
2Hematology, Hebrew University-Hadassah Medical Organization , Jerusalem, Israel
3Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel
4Hematology Mt. Scopus, Hebrew University-Hadassah Medical Organization, Jerusalem, Israel

Treatment with the PI3K/mTOR Inhibitor, NVP-BEZ235, Overcomes Resistance to Imatinib in Quiescent or T315I-Mutated Ph+ Leukemia Cells

Yosuke Minami, MD, PhD, Miho Minami*, Nobuaki Fukushima*, Yachiyo Kuwatsuka* and Tomoki Naoe, MD, PhD

Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan

Clinical Significance of CD33 Non-Synonymous Single Nucleotide Polymorphisms (SNPs) in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab Ozogamicin-Containing Chemotherapy

Jatinder Lamba, PhD1, Leslie J. Mortland, MD2, Amit Mitra1*, Roland B. Walter, MD, PhD3,4, Jessica A. Pollard, MD3, Todd A. Alonzo, PhD5, Robert B. Gerbing, M.A.6*, Betsy A. Hirsch, PhD7*, Susana C. Raimondi, PhD8, Janet Franklin, MD, MPH9 and Soheil Meshinchi, MD, PhD3

1Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN
2University of Minnesota
3Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
4Department of Medicine/Division of Hematology, University of Washington, Seattle, WA
5COG & Keck School of Medicine, University of Southern California, Los Angeles, CA
6Children's Oncology Group
7Division of Laboratory Medicine, University of Minnesota Medical Center-Fairview, Minneapolis, MN
8Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
9Amgen, Inc, Thousand Oaks, CA

Aberrant MAPK and PI3K Signaling Contribute to Chemotherapy Resistance in T Cell Acute Lymphoblastic Leukemia by Altering the Balance of Apoptosis Mediators

Justin Wahlstrom, MD, Kristin Ammon, MD*, Christopher Esquivel, B.A.*, Jason Law, MD and Michelle L. Hermiston, MD, PhD

UCSF, Children's Hospital, San Francisco, CA

Resistance to Selective FLT3 Inhibitors, Driven by FLT3 Ligand and FLT3 Point Mutations, Can Be Overcome with the Dual FLT3-Aurora Kinase Inhibitor CCT241736

Andrew S. Moore, MBBS, FRACP1*, Amir Faisal1*, Vassilios Bavetsias1*, David Gonzalez de Castro, PhD2*, Chongbo Sun1*, Butrus Atrash1*, Melanie Valenti1*, Alexis de Haven Brandon1*, Sian Avery1*, Andrew DJ Pearson1*, Paul Workman1*, Julian Blagg1*, Florence I Raynaud1*, Suzanne A Eccles1* and Spiros Linardopoulos1*

1Division of Cancer Therapeutics, The Institute of Cancer Research, Sutton, United Kingdom
2Division of Molecular Pathology, The Institute of Cancer Research, Sutton, United Kingdom

PI3K Inhibition As a Potential Therapeutic Strategy in Peripheral T-Cell Lymphomas

Esperanza Martin-Sanchez1*, Socorro M. Rodriguez-Pinilla1*, Luis Lombardia2*, Beatriz Dominguez-Gonzalez1*, Margarita Sanchez-Beato1*, Diana Romero2*, Magdalena B. Wozniak1*, Manuela Mollejo, MD3*, Javier Alves4*, Jose Luis Rodriguez-Peralto5*, Javier Menarguez6*, Juan C. Cigudosa7, Pablo L. Ortiz-Romero8*, Juan F. Garcia, MD9*, James R. Bischoff10* and Miguel A. Piris1,11*

1Lymphoma Group, Spanish National Cancer Research Centre, Madrid, Spain
2Molecular Diagnostic Unit, Spanish National Cancer Research Centre, Madrid, Spain
3Hospital Virgen de la Salud, Toledo, Spain
4Pathology, Hospital Universitario La Paz, Madrid, Spain
5Pathology, Hospital 12 de Octubre, Madrid, Spain
6Pathology, Hospital General Univ. Gregorio Marañon, Madrid, Spain
7Human Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
8Dermatology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
9Pathology, MD Anderson Cancer Centre, Madrid, Spain
10Experimental Therapeutics Programme, Spanish National Cancer Research Centre, Madrid, Spain
11Pathology Department, Hospital Universitario Marques de Valdecilla, IFIMAV, Santander, Spain

PIM Kinases Inhibition, a Rational Strategy in Peripheral T-Cell Lymphomas

Esperanza Martin-Sanchez1*, Socorro M. Rodriguez-Pinilla1*, Margarita Sanchez-Beato1*, Beatriz Dominguez-Gonzalez1*, Magdalena B. Wozniak1*, Manuela Mollejo, MD2*, Javier Alves3*, Jose Luis Rodriguez-Peralto4*, Javier Menarguez5*, Juan C. Cigudosa6, Pablo L. Ortiz-Romero7*, Juan F. Garcia, MD8*, James R. Bischoff9* and Miguel A. Piris1,10*

1Lymphoma Group, Spanish National Cancer Research Centre, Madrid, Spain
2Hospital Virgen de la Salud, Toledo, Spain
3Pathology, Hospital Universitario La Paz, Madrid, Spain
4Pathology, Hospital 12 de Octubre, Madrid, Spain
5Pathology, Hospital General Univ. Gregorio Marañon, Madrid, Spain
6Human Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
7Dermatology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
8Pathology, MD Anderson Cancer Centre, Madrid, Spain
9Experimental Therapeutics Programme, Spanish National Cancer Research Centre, Madrid, Spain
10Pathology Department, Hospital Universitario Marques de Valdecilla, IFIMAV, Santander, Spain

Functional Characterization of ABCG2 Polymorphisms and Their Influence on Tyrosine Kinase Inhibitor Effects in Chronic Myeloid Leukemia Cells

Karin Skoglund1*, Samuel Boiso Moreno1*, Jan-Ingvar Jönsson2* and Henrik Gréen1,3*

1Division of Drug Research/Clinical Pharmacology, Linköping University, Linköping, Sweden
2Division of Cell Biology, Linköping University, Linköping, Sweden
3Science for Life Laboratory, Royal Institute of Technology, Solna, Sweden

PIM2 Upregulation Leads to Physiological Buffering of Metformin-Induced Cell Death Mediated by ER Stress/UPR in Acute Lymphoblastic Leukemia

Gilles M. Leclerc, Ph.D.1*, Guy J. Leclerc, Ph.D.1*, Jeffim N. Kuznetsov, B.Sc.2* and Julio C. Barredo, M.D.3

1Pediatrics Hematology and Oncology, University of Miami Miller School of Medicine, Miami, FL
2Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL
3Pediatrics and Biochemistry and Molecular Biology, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, FL

Ponatinib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest and Apoptosis

Karoline V. Gleixner, M.D.1*, Katharina Blatt, M.Sc.1*, Barbara Peter, D.V.M.2*, Emir Hadzijusufovic, DVM1,3* and Peter Valent, M.D.1,2

1Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
2Ludwig Boltzmann Cluster Oncology, Vienna, Austria
3Department for Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine of Vienna, Vienna, Austria

Targeting the Cyclin D - CDK4/6 - Rb Axis in Mantle Cell Lymphoma with the Novel Translation Inhibitor Silvestrol

Lapo Alinari, MD., Ph.D.1, Ryan B. Edwards1*, Courtney J. Prince1*, William H. Towns1*, Rajeswaran Mani, DVM2*, Amy Lehman3*, Xiaoli Zhang, PhD, MS3*, David Jarjoura, PhD3*, Li Pan, PhD4*, A. Douglas Kinghorn, PhD, DSc1*, Michael R. Grever, M.D.1, Robert A. Baiocchi, M.D., Ph.D.1 and David M. Lucas, PhD1

1Ohio State University Comprehensive Cancer Center, Columbus, OH
2Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
3Center for Biostatistics, Ohio State University Comprehensive Cancer Center, Columbus, OH
4 Ohio State University Comprehensive Cancer Center, Columbus, OH

Cytotoxic Activity of Anti-CD20-hIFN-α on Rituximab-Resistant B-NHL Clones and Synergy with Chemotherapy

Gabriel G Vega, MDVZ1*, Mario I Vega, PhD1,2, Sara Huerta-Yepez, Ph.D.3*, Ali Jazirehi, PhD4*, Hector Mayani, PhD1*, Otoniel Martinez-Maza, PhD5*, Sherie Morrison6* and Benjamin Bonavida, Ph.D7

1Oncology Hospital, Oncology Research Unit, Siglo XXI National Medical center IMSS, Mexico City, Mexico
2Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine UCLA, Los Angeles, CA
3Unidad de Investigación en Enfermedades Oncológicas, Hospital Infantil de México Federico Gómez, Mexico D.F., Mexico
4Department of Microbiology, Immunology & Molecular Genetics, UCLA David Geffen School of Medicine, Jonsson Comprehensive Cancer Center, Los Angeles, CA
5Microbiology Immunology and Molecular Genetics, David Geffen School of Medicine UCLA, Los Angeles, CA
6MIMG, University of California, Los Angeles, Los Angeles, CA
7Department of Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine, UCLA, Los Angeles, CA

FLT3-ITD+ AML Blast, Progenitor and Stem Cell Populations Demonstrate Higher Sensitivity to the Hsp90 Inhibitor PU-H71

Hongliang Zong, MD, PhD1*, Tony Taldone, PhD2*, James H. Ahn2*, Sarah Brennan, PhD1*, Jeanne P. De Leon3*, Michael W. Becker, MD4*, Gail J. Roboz, MD1, Gabriela Chiosis, PhD2* and Monica L. Guzman, PhD1

1Division of Hematology/Oncology Dept. of Medicine, Weill Cornell Medical College, New York, NY
2Memorial Sloan Kettering Cancer Center, New York, NY
3Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY
4Hematology Oncology, University of Rochester Medical Center, Rochester, NY

Non-Steroidal Anti-Inflammatory Drugs and Imatinib; Drug Interactions That May Impact Efficacy

Jueqiong Wang, MMed1,2*, Timothy P Hughes, MD, MBBS1,2,3, Chung Hoow Kok, PhD1,2*, Verity A Saunders, BScHons1*, Amity Frede, BScHons1*, Kelvin GrootObbink, BScHons1*, Michael Philip Osborn, MBBS1,4*, Andrew A Somogyi, PhD3,5*, Richard J D'Andrea, PhD1,2,3,6 and Deborah L. White, PhD. FFSc(RCPA)1,2,3

1Department of Haematology, Centre for Cancer Biology/SA Pathology (RAH site), Adelaide, Australia
2School of Medicine, University of Adelaide, Adelaide, Australia
3Centre for Personalised Cancer Medicine, University of Adelaide, Adelaide, Australia
4Women’s and Children’s Hospital, Adelaide, Australia
5Discipline of Pharmacology, University of Adelaide, Adelaide, Australia
6Haematology and Oncology, The Queen Elizabeth Hospital, Adelaide, Australia

Phospho-Specific Flow Cytometry of Fixed Whole Blood Demonstrates In Vivo FLT3 Inhibition in Circulating Leukemic Blasts During AC220 Therapy and Accurately Detects the Development of Therapeutic Resistance

Alexander E Perl, MD1, Grace R Jeschke1*, Catherine C. Smith, MD2, James K. Mangan, MD, PhD1, Selina M. Luger, MD1 and Martin Carroll, MD1

1Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
2Department of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA

Genome-Wide shRNA Screen Identifies WEE1 As a Critical Mediator of Cell Fate and Novel Therapeutic Target in AML

Christopher C. Porter, MD1, Jihye Kim, Ph.D.2*, Susan Fosmire1*, Christy M. Gearheart, Ph.D.1*, Annemie van Linden, Ph.D.1*, Vadym Zaberezhnyy3*, Dexiang Gao, Ph.D.2*, Aik Choon Tan, Ph.D.2* and James DeGregori, Ph.D.1,3*

1Pediatrics, UC Denver, Aurora, CO
2Biostatistics and Informatics, UC Denver, Aurora, CO
3Biochemistry & Molecular Genetics, UC Denver, Aurora, CO

Cryptic Intracellular Retention of ABL Tyrosine Kinase Inhibitors within CML Cells Mediates Apoptosis Commitment Following Acute Drug Exposure

Thomas O'Hare1, Christopher A. Eide2,3*, Lauren T. Adrian2*, Anupriya Agarwal, PhD2*, Matthew S. Zabriskie2,3*, Ryan MacKenzie, BS2*, Dorian H. LaTocha, BS2*, Huihong You, PhD2*, Jenny Luo, BS4*, Steven M. Riddle, PhD5*, Bryan Marks, PhD5*, Dennis R. Koop, PhD4*, John Apgar, PhD6*, Michael W. Deininger1 and Brian J. Druker, MD2,3

1Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
2Knight Cancer Institute, Oregon Health & Science University, Portland, OR
3Howard Hughes Medical Institute, Portland, OR
4Physiology and Pharmacology/Bioanalytical Shared Resource/Pharmacokinetics Core, Oregon Health & Science University, Portland, OR
5Life Technologies, Madison, WI
6BD Biosciences, San Diego, CA

Acquired Point Mutations of TKD Are Responsible for Sorafenib Resistance in FLT3-ITD Mutant AML

Weiguo Zhang, M.D., Ph.D.1, Marina Konopleva, M.D., Ph.D.2, Rodrigo O Jacamo, Ph.D.3*, Gautam Borthakur, M.D4, Wenjing Chen5*, Jorge E. Cortes, MD6, Farhad Ravandi, MD7 and Michael Andreeff, M.D., Ph.D.3

1Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
2Section of Molecular Hematology & Therapy, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center , Houston, TX
3Section of Molecular Hematology & Therapy, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
4The University of Texas M.D. Anderson Cancer Center, Houston, TX
5Leukemia, M.D. Anderson Cancer Center, Houston, TX
6Leukemia Department, The University of Texas M.D. Anderson Cancer Center, Houston, TX
7Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Targeting Redox Homeostasis As a Means to Selectively Eradicate Primary Human Leukemia Cells

Shanshan Pei1*, Kevin Callahan, PhD2*, Mohammad Minhajuddin, PhD2*, Marlene Balys2*, Sarah Neering2*, Cheryl Corbett2*, Michael W. Becker, MD3*, Jane L. Liesveld, MD3, Fred Hagen, PhD4*, Alan E Friedman, PhD5*, Peter Crooks, PhD6* and Craig T. Jordan, PhD2

1Department of Biomedical Genetics, University of Rochester School of Medicine and Dentistry, Rochester, NY
2Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY
3Hematology Oncology, University of Rochester Medical Center, Rochester, NY
4Department of Biochemistry and Biophysics, University of Rochester Medical Center, Rochester, NY
5Molecular Toxicology & Environmental Medicine Cluster, University of Rochester Medical Center, Rochester, NY
6College of Pharmacy, University of Arkansas for Medical Sciences, Lexington, KY

MDR-1 and GST Polymorphisms Are Involved in Myelodysplasia Progression 

Bruna Palodetto, B.Sc*, Bruno Deltreggia Benites, MD*, Paula de Melo Campos, M.D.*, Fabíola Traina, MD, PhD* and Sara T Olalla Saad, MD, PhD

Hematology and Hemotherapy Center, University of Campinas-UNICAMP, INCT do Sangue, Campinas-SP, Brazil

Phospho-Specific Flow Cytometry of Fixed Whole Blood During AML Clinical Trials to Monitor In Vivo FLT3 Inhibition in Leukemic Blasts

Alexander E Perl, MD1, Grace R Jeschke1*, Takashi Sato2*, Shiro Akinaga3*, Niranjan S. Rao, PhD4*, Maria R. Baer, MD5, Mark J. Levis, MD, PhD6 and Martin Carroll, MD1

1Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
2Kyowa Hakko Kirin Co., LTD, Matsudo, Japan
3Development Division, Kyowa Hakko Kirin Co., Ltd., Chiyoda-ku, Japan
4Clinical Pharmcology, Kyowa Pharmaceutical, Inc., Princeton, NJ
5Greenebaum Cancer Center, University of Maryland, Baltimore, MD
6Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Combining Tetrahydrouridine with Decitabine Addresses Malignant Cell Sanctuary in the Liver, a Tissue That Expresses High Levels of Cytidine Deaminase

Quteba Ebrahem, MD1*, Reda Z Mahfouz, MD2, Kwok Ng Peng, PhD1* and Yogen Saunthararajah, MD3,4

1cleveland clinic, cleveland, OH
2Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH
3Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic,Taussig Cancer Institute, Cleveland, OH

The Novel Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Potent Cytotoxicity in Primary Chronic Lymphocytic Leukemia Cells and a Defective NF-κB Response

Sneha V. Gupta*, Erin K Hertlein, PhD, Jennifer A. Woyach, MD, Ellen J. Sass*, Melanie E. Davis*, John C. Byrd, MD and David M. Lucas, PhD

Ohio State University Comprehensive Cancer Center, Columbus, OH

Caspase-8 Determines Chemosensitivity of ALL Cells and Mediates Favorable Interactions of Cytotoxic Drugs

Harald Ehrhardt, MD1* and Irmela Jeremias, MD1,2

1Dr. von Haunersches Kinderspital, Ludwig Maximilians Universität München, Munich, Germany
2Gene Vectors, Helmholtz Zentrum, Munich, Germany

CX-4945, An Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Hematologic Malignancies

Renee C Prins, M.D.1*, Stephen Spurgeon, MD2,3, Jeffrey W Tyner, PhD4,5*, Luke B Fletcher6*, Abdusebur Jemal7*, Jade A Bryant, BS6*, Russell T Burke6*, Bill H Chang, MD, PhD7,8, Tibor Kovacsovics, MD1,5*, Brian J. Druker, MD2,3,9 and Marc M Loriaux, MD, PhD6,10

1Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR
2Knight Cancer Institute, Oregon Health and Science University, Portland, OR
3Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR
4Division of Hematology and Medical Oncology, Oregon Health & Science University , Portland, OR
5Knight Cancer Institute, Oregon Health & Science University , Portland, OR
6Knight Cancer Institute, Oregon Health & Science University, Portland, OR
7Oregon Health & Science University Knight Cancer Institute, Portland, OR
8Divsion of Hematology and Medical Oncology, Doernbecher's Children's Hospital, Portland
9Howard Hughes Medical Institute, Portland, OR
10Department of Pathology, Oregon Health & Science University, Portland, OR

RNAi Screening Identifies BCL-XL As An Erythroid Lineage-Specific 5-Azacytidine Sensitizer While the BCL-2/BCL-XL/BCL-W Inhibitor ABT-737 Results in More Universal Sensitization in Leukemia Cells

James M Bogenberger, PhD1*, Chang-Xin Shi2*, Irma Gonzales3*, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA4, Pierre Noel, MD5, James L. Slack, MD5, Ruben A. Mesa, MD6, Keith Stewart, MBA, MB, CHB2, Yihua Qiu7*, Kevin R Coombes8*, Steven M. Kornblau, MD9, David Azorsa, PhD3* and Raoul Tibes, MD, PhD5*

1Mayo Clinic, Scottsdale, AZ
2Research, Mayo Clinic, Scottsdale, AZ
3TGen, Scottsdale, AZ
4Hematology/Oncology, Mayo Clinic, Scottsdale, AZ
5Division of Hematology and Medical Oncology, Mayo Clinic in Arizona, Scottsdale, AZ
6Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ
7Molecular Hematology & Therapy, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
8Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX
9M.D. Anderson Cancer Center, Houston, TX

*signifies non-member of ASH